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The Arg/N-degron pathway targets proteins for degradation by
recognizing their N-terminal (Nt) residues. If a substrate bears,
for example, Nt-Asn, its targeting involves deamidation of Nt-
Asn, arginylation of resulting Nt-Asp, binding of resulting (conju-
gated) Nt-Arg to the UBR1-RAD6 E3-E2 ubiquitin ligase, ligase-
mediated synthesis of a substrate-linked polyubiquitin chain, its
capture by the proteasome, and substrate’s degradation. We dis-
covered that the human Nt-Asn–specific Nt-amidase NTAN1, Nt-
Gln–specific Nt-amidase NTAQ1, arginyltransferase ATE1, and the
ubiquitin ligase UBR1-UBE2A/B (or UBR2-UBE2A/B) form a complex
in which NTAN1 Nt-amidase binds to NTAQ1, ATE1, and UBR1/
UBR2. In addition, NTAQ1 Nt-amidase and ATE1 arginyltransferase
also bind to UBR1/UBR2. In the yeast Saccharomyces cerevisiae,
the Nt-amidase, arginyltransferase, and the double-E3 ubiquitin
ligase UBR1-RAD6/UFD4-UBC4/5 are shown to form an analogous
targeting complex. These complexes may enable substrate chan-
neling, in which a substrate bearing, for example, Nt-Asn, would
be captured by a complex-bound Nt-amidase, followed by sequen-
tial Nt modifications of the substrate and its polyubiquitylation at
an internal Lys residue without substrate’s dissociation into the
bulk solution. At least in yeast, the UBR1/UFD4 ubiquitin ligase
interacts with the 26S proteasome, suggesting an even larger
Arg/N-degron–targeting complex that contains the proteasome
as well. In addition, specific features of protein-sized Arg/
N-degron substrates, including their partly sequential and partly
nonsequential enzymatic modifications, led us to a verifiable con-
cept termed “superchanneling.” In superchanneling, the synthesis
of a substrate-linked poly-Ub chain can occur not only after a
substrate’s sequential Nt modifications, but also before them,
through a skipping of either some or all of these modifications
within a targeting complex.
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Regulated protein degradation protects cells from abnormal(e.g., misfolded or aggregated) proteins, and also mediates
the levels of proteins that evolved to be constitutively or condi-
tionally short-lived in vivo. The ubiquitin (Ub)-proteasome sys-
tem (UPS) and the autophagy-lysosome system comprise two
major sets of intracellular proteolytic pathways. Chaperone
proteins are a part of both systems (1–10). Ub ligases of the UPS
recognize substrate proteins through their degradation signals
(degrons) and conjugate the 9-kDa Ub (usually a poly-Ub chain)
to cognate amino acid residues (usually specific internal lysines)
of targeted substrates. Deubiquitylases, another major class of
UPS enzymes, catalyze deubiquitylation of Ub-conjugated pro-
teins (2–4, 9–13). A substrate-linked poly-Ub chain is recognized
by the ATP-dependent protease called the 26S proteasome. This
protease unfolds the captured protein and processively converts
it to ∼10-residue peptides (14–19).
Several proteolytic systems, called N-degron pathways (pre-
viously called “N-end rule pathways”), have in common their
ability to recognize proteins that contain N-terminal (Nt)
degrons called N-degrons. This recognition causes degradation
of targeted proteins by the 26S proteasome and autophagy in
eukaryotes, and by the proteasome-like ClpAP protease in bac-
teria (Fig. 1 and SI Appendix, Fig. S1) (2, 9, 10, 20–48). An
N-degron comprises, in particular, a destabilizing Nt-residue of
a protein and its internal Lys residue(s) that acts as a site of
polyubiquitylation (2, 21, 49).
Eukaryotes contain the Arg/N-degron pathway (it recognizes,
in particular, specific unacetylated Nt-residues) (Fig. 1), the Ac/
N-degron pathway (it recognizes, in particular, the Nα-terminally
acetylated [Nt-acetylated] Nt-residues), the Pro/N-degron path-
way (it recognizes, in particular, the Nt-Pro residue or a Pro at
position 2), the Gly/N-degron pathway (it recognizes Nt-Gly),
and the fMet/N-degron pathway (it recognizes proteins that had
been “pretranslationally” Nt-formylated) (SI Appendix, Fig. S1)
(2, 9, 10, 22–24, 26, 27, 46–48, 50).
Most N-degrons are initially cryptic (pro-N-degrons). They
become active N-degrons either constitutively (e.g., cotransla-
tionally) or via regulated steps. Nonprocessive proteases, in-
cluding caspases, calpains, separases, and cathepsins, act as
specific components of N-degron pathways, since a cleavage of a
protein can generate a C-terminal (Ct) fragment bearing an
N-degron (9, 10, 33, 46, 51, 52). Active N-degrons can also be
formed through enzymatic Nt-acetylation, Nt-deamidation, Nt-
oxidation, Nt-arginylation, Nt-leucylation, and Nt-formylation of
specific proteins (Fig. 1 and SI Appendix, Fig. S1). Recognition
components of N-degron pathways are called N-recognins. They
are E3 Ub ligases or other proteins, for example, mammalian
p62 or bacterial ClpS, that can recognize N-degrons (2, 6, 9, 10,
23, 24, 41). In cognate sequence contexts, all 20 amino acids of
the genetic code are capable of functioning as destabilizing Nt-
residues (SI Appendix, Fig. S1). Consequently, many proteins in a
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cell are constitutive or conditional N-degron substrates, either as
full-length proteins or as Ct-fragments.
Regulated degradation of proteins or their natural fragments
by N-degron pathways has been shown to function in a large
number of biological processes, including the sensing of short
peptides, heme, oxygen, and nitric oxide (NO); the regulation of
subunit stoichiometries in oligomeric proteins; the elimination of
misfolded proteins; the control of DNA repair, transcription,
replication, and chromosome cohesion/segregation; the regula-
tion of G proteins, chaperones, cytoskeletal proteins, gluconeo-
genesis, autophagy, peptide transport, meiosis, circadian rhythms,
cell migration, fat metabolism, immunity (including inflammation),
cardiovascular system, neurogenesis, and spermatogenesis; a sup-
pression of neurodegeneration and regulation of apoptosis; and also
plant cell differentiation, plant defenses against pathogens, the
sensing of oxygen and NO, and many other processes in plants (refs.
2, 9, 10, 20, 22–32, 34, 36–47, 50, 53–57, and references therein).
To keep notations uniform, human genetic terms (all-uppercase
letters) are used below to denote both human (Homo sapiens, hs)
and yeast (Saccharomyces cerevisiae, sc) genes and proteins.
scUBR1 encodes the 225-kDa RING-type E3, denoted as scUBR1,
that functions as the sole N-recognin of the S. cerevisiae Arg/
N-degron pathway. Unmodified Nt-Arg, Nt-Lys, Nt-His, Nt-Leu,
Nt-Phe, Nt-Tyr, Nt-Trp, Nt-Ile, and Nt-Met (if Met is followed by a
bulky hydrophobic residue) are “primary” destabilizing Nt-residues
in that they are directly bound by scUBR1 (Fig. 1A) (2, 20, 22, 33,
34, 36, 51, 58–60). In contrast, Nt-Asp and Nt-Glu are destabilizing
because of their Nt-arginylation by scATE1 arginyltransferase
(R-transferase). The resulting (conjugated) Nt-Arg is bound by
scUBR1. Nt-Asn and Nt-Gln are destabilizing since scNTA1 Nt-
amidase converts them to Nt-arginylatable Nt-Asp and Nt-Glu
(Fig. 1A) (61, 62). scUBR1 E3 contains multiple binding sites that
can target not only N-degrons but also other degrons in specific
N-degron–lacking proteins (9, 57, 63, 64). scUBR1 E3 is bound to
its cognate E2 (Ub-conjugating) enzyme scRAD6, and also to a
complex of scUFD4 E3 with its cognate E2 enzyme (scUBC4 or
scUBC5) (Fig. 1A) (65).
In contrast to S. cerevisiae, the human genome encodes at least
four N-recognin E3s, the 200-kDa hsUBR1 and hsUBR2, the
570-kDa hsUBR4 (p600, BIG), and the 300-kDa hsUBR5
(EDD1, HYD) (Fig. 1B) (2, 24, 66–68). Yet another N-recognin
of the human Arg/N-degron pathway is p62, an autophagy-
regulating protein distinct from E3s (41, 69, 70). hsUBR1 and
hsUBR2 E3s are sequelogous (similar in sequence) (71) (they
Fig. 1. (A) The S. cerevisiae Arg/N-degron pathway. Nt-residues are denoted by single-letter abbreviations. Yellow ovals denote the rest of a protein sub-
strate. “Primary,” “secondary,” and “tertiary” refer to mechanistically distinct classes of destabilizing Nt-residues. “Type 1” and “type 2” refer, respectively, to
two sets of primary destabilizing Nt-residues, basic (Arg, Lys, His) and bulky hydrophobic (Leu, Phe, Trp, Tyr, Ile, and also Met, if the latter is followed by a
bulky hydrophobic residue [V]). These Nt-residues are recognized by two substrate-binding sites (type 1 and type 2) of scUBR1, the pathway’s E3 N-recognin.
(B) The mammalian Arg/N-degron pathway. Hemin (Fe3+-heme) inhibits the activity of R-transferase and accelerates its degradation in vivo. Hemin also binds
to UBR1/UBR2 E3s and inhibits specific aspects of their activity (2, 22, 24). Besides recognizing Arg/N-degrons, E3s of the Arg/N-degron pathway contain, in
addition, specific binding sites that are exposed conditionally and recognize non-Nt degrons of proteins that lack Arg/N-degrons (2, 9, 22, 24). See In-
troduction for references and other details. See also SI Appendix, Fig. S1 for other N-degron pathways.
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are 47% identical) to each other and to S. cerevisiae scUBR1 (6).
In contrast, sequelogies (sequence similarities†) between
hsUBR1/hsUBR2 and hsUBR4 or hsUBR5 are confined largely
to their ∼80-residue UBR domains, which recognize N-degrons
that bear N-terminal Arg, Lys, or His (Fig. 1B) (2, 59, 60). An-
imals and plants contain two Nt-amidases, the Nt-Asn-specific
NTAN1, and the Nt-Gln-specific NTAQ1 (47, 50, 72). At least in
multicellular eukaryotes, Nt-arginylation encompasses not only
Nt-Asp and Nt-Glu but also Nt-Cys, after its conditional (oxygen/
NO-dependent) oxidation to Nt-Cys-sulfinate or Nt-Cys-sulfonate
(Fig. 1B) (44, 47, 55, 73–75).
Degradation, by the human Arg/N-degron pathway, of a sub-
strate bearing, for example, Nt-Asn involves deamidation of Nt-
Asn by the Asn/Nt-amidase hsNTAN1; Nt-arginylation of
resulting Nt-Asp by the hsATE1 R-transferase; the binding of
resulting (conjugated) Nt-Arg to the hsUBR1 (or hsUBR2) E3
component of the E3-E2 Ub ligase; the ligase-mediated synthesis
of a poly-Ub chain linked to a substrate’s internal Lys residue;
the capture of substrate (at least in part through its poly-Ub) by
the 26S proteasome; and the substrate’s processive degradation
by the proteasome (Fig. 1B).
In the present study, we discovered that the Asn/Nt-amidase
hsNTAN1, the Gln/Nt-amidase hsNTAQ1, the R-transferase
hsATE1, and the E3-E2 Ub ligase hsUBR1–hsUBE2A/B (or
hsUBR1–hsUBE2A/B) (Fig. 1B) form a targeting complex of the
human Arg/N-degron pathway. In addition, the yeast Nt-amidase
scNTA1, the R-transferase scATE1, and the double-E3 Ub li-
gase scUBR1–scRAD6/scUFD4–scUBC4/5 (Fig. 1A) were found
to form an analogous targeting complex of the S. cerevisiae Arg/
N-degron pathway. Previous work by this laboratory showed that
scUBR1 and scUFD4 E3s, which bind to each other (65), also bind to
the 26S proteasome (76). That evidence, if viewed together with re-
sults of the present study, suggests an even larger N-degron–targeting
complex that contains the proteasome as well.
Enzymes or assemblies of enzymes that catalyze sequential re-
actions have been observed to exhibit substrate channeling, in
which a reaction intermediate can be transferred between active
sites of interacting enzymes without release of intermediate to the
bulk solution (77–85). It remains to be determined whether tar-
geting complexes identified in the present work function to enable
substrate channeling.
Specific features of protein-sized Arg/N-degron substrates and
targeting complexes that capture them led us to a verifiable
concept, termed “superchanneling.” This mechanism is mutually
nonexclusive vis-à-vis substrate channeling. In superchanneling,
the last modification of a substrate, i.e., the synthesis of a
substrate-linked poly-Ub chain can bypass sequential Nt modi-
fications of the substrate by skipping, within a targeting complex,
some or all of these modifications. We discuss predictions of the
superchanneling model and approaches to its verification.
Results and Discussion
Protein Binding Assays. Our previous (28, 86) and present work
employed the yeast-based two-hybrid (Y2H) method of Fields
and colleagues (87–89) for detecting in vivo protein interactions.
In assays with Y2H-based protein fusions, we varied locations
(Nt or Ct) of a fusion’s activation domain (AD) or DNA-binding
domain (DBD), particularly if an initial Y2H assay did not detect
an interaction. Controls included immunoblotting to examine
Y2H-based fusions, and also verifying that binding-positive Y2H
fusions were not autoactivating, i.e., that none of them were
positive in Y2H assays that contained just one of two fusions.
The results summarized below passed all of these controls. This
study also employed split-Ub, glutathione transferase (GST)-
pulldown, and coimmunoprecipitation (co-IP) binding assays
(Figs. 2–5 and SI Appendix, Figs. S2–S10).
Human hsUBR1 and hsUBR2 E3s Bind to the Nt-Asn–Specific Nt-Amidase
hsNTAN1. Y2H assays with the full-length 200-kDa hsUBR1
E3 N-recognin vs. the Asn/Nt-amidase hsNTAN1 revealed their
interaction (Figs. 1B and 2, rows 1 to 3). Y2Hs with hsUBR2 E3
yielded similar results, in that hsUBR2 also interacted with
hsNTAN1 (SI Appendix, Fig. S2, rows 1 to 3).
Human hsUBR1 and hsUBR2 E3s Bind to the Nt-Gln–Specific Nt-Amidase
hsNTAQ1. Nt-amidases catalyze similar reactions (Fig. 1). Never-
theless, the human Asn/Nt-amidase hsNTAN1 is not sequelogous to
either the human Gln/Nt-amidase hsNTAQ1 or the S. cerevisiaeNt-
amidase scNTA1, which can deamidate both Nt-Asn and Nt-Gln
(47, 50, 62, 72). The absence of sequelogy suggests independent
evolutionary origins of the three Nt-amidases. Y2Hs indicated the
binding of both hsNTAQ1 and hsNTAN1 to both hsUBR1 E3 and
hsUBR2 E3 (Figs. 1B and 2, rows 1 to 6, and SI Appendix, Fig. S2,
rows 1 to 9, SI Appendix, Fig. S5, row 1, and SI Appendix, Fig. S6,
row 17).
To address these interactions in a different way, we also used
GST-pulldown assays (64, 90). GST alone as well as hsNTAN1–
GST and GST–hsNTAQ1 fusions were expressed in Escherichia
coli, purified, and immobilized on glutathione-Sepharose beads (SI
Appendix, Fig. S9 A and B). Equal amounts of extract from
S. cerevisiae that expressed the N-terminally flag-tagged human
Fig. 2. Y2H binding assays, in wild-type (UBR1 UFD4) S. cerevisiae, with
enzymes of the human Arg/N-degron pathway. Expression of HIS3, the as-
says’ readout in otherwise His− cells, is a function of binding affinity be-
tween test proteins (87). Histidine-lacking plates (shown on the right) were
incubated for ∼2 d at 30 °C to detect the growth of His+ cells. Nt and Ct Y2H-
specific domains in Y2H-based protein fusions are marked in red. Row 1,
hsNTAN1 vs. vector alone. Row 2, hsUBR1 vs. vector alone. Row 3, hsUBR1 vs.
hsNTAN1. Row 4, hsNTAQ1 vs. vector alone. Row 5, hsUBR1 vs. vector alone.
Row 6, hsNTAQ1 vs. hsUBR1. Row 7, hsNTAN1 vs. vector alone. Row 8,
hsNTAQ1 vs. vector alone. Row 9, hsNTAN1 vs. hsNTAQ1. Row 10, hsATE1 vs.
vector alone. Row 11, hsNTAN1 vs. vector alone. Row 12, hsATE1 vs.
hsNTAN1. See also SI Appendix, Materials and Methods.
†
“Sequelog” denotes a sequence that is similar, to a specified extent, to another sequence
(71). Derivatives of sequelog include “sequelogy” (sequence similarity) and “sequelo-
gous” (similar in sequence). The usefulness of sequelog and derivative notations stems
from the rigor and clarity of their evolutionary neutrality. In contrast, in settings that use
“homolog,” “ortholog,” and “paralog” (they denote, respectively, common descent and
functional similarity/dissimilarity), these terms are often interpretation-laden and can be
imprecise. Homolog, ortholog, and paralog are compatible with the sequelog terminol-
ogy. The former terms can be used to convey understanding about common descent and
biological functions, if this additional information, distinct from sequelogy per se, is
actually present (71).
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fhsUBR2 E3 were incubated with the above (preloaded on beads)
GST or GST fusions, followed by washes, elution of beads-
associated proteins, their SDS/PAGE, and immunoblotting for
fhsUBR2 with anti-flag antibody. In agreement with the above Y2H
results, fhsUBR2 interacted with both hsNTAN1–GST and GST–
hsNTAQ1, but did not bind to GST alone (Fig. 4D).
The Human Asn/Nt-Amidase hsNTAN1 Binds to the Gln/Nt-Amidase
hsNTAQ1. In addition to their binding to the hsUBR1 (and
hsUBR2) E3 Ub ligases, the hsNTAN1 and hsNTAQ1 Nt-amidases
were also found to interact with each other, in the absence of both
hsUBR1 and hsUBR2 (Fig. 2, rows 7 to 9). On the assumption (it
remains to be verified) that pairwise interactions among hsNTAN1,
hsNTAQ1, and hsUBR1 (or hsUBR2) are mutually nonexclusive,
these binding modes would be multivalent and would be expected,
therefore, to increase the overall stability of the tripartite
hsNTAN1–hsNTAQ1–hsUBR1 complex, in comparison to pairwise
interactions within the complex (Fig. 6A).
The Human hsATE1 R-Transferase Binds to hsNTAN1 Asn/Nt-Amidase.
ATE1 R-transferase conjugates Arg to Nt-Asp, Nt-Glu, or oxi-
dized Nt-Cys. The R-transferase branch of the Arg/N-degron path-
way is a sensor of oxygen and NO in animals and plants (Introduction
and Fig. 1B) (44, 73, 74, 91, 92). Using Y2H-based hsATE1 fusions
(tagged with Nt-DBD or Ct-DBD domains), we found that
hsATE1 R-transferase binds to hsNTAN1 Asn/Nt-amidase (Fig. 2,
rows 10 to 12, and SI Appendix, Fig. S2, rows 13 to 15).
The Human hsATE1 R-Transferase Does Not Bind to hsNTAQ1 Gln/
Nt-Amidase. In contrast to the binding of hsATE1 R-transferase
to Asn/Nt-amidase hsNTAN1 (see above), Y2Hs were negative
with hsATE1 vs. Gln/Nt-amidase hsNTAQ1. These results are
shown here for Nt-DBD/hsNTAQ1 vs. Nt-AD/hsATE1 (SI Ap-
pendix, Fig. S2, rows 10 to 12), and similar results (no in-
teraction) were obtained with all eight Nt/Ct permutations of the
DBD and AD domains linked to hsNTAQ1 and hsATE1.
To address this question in a different way, we used a yeast-
based split-Ub assay (93, 94). In split-Ub, proteins are expressed
as fusions, respectively, to a Ct-half of Ub (CUb) and to its mu-
tant Nt-half (NUb). Interactions between test proteins would
reconstitute a quasi-native Ub moiety from CUb and mutant NUb,
causing the cleavage of a CUb-containing fusion by deubiquity-
lases downstream from (reconstituted) Ub moiety. Through ad-
ditional steps, this cleavage acts as readout of split-Ub assays (93,
94). In agreement with Y2H assays (SI Appendix, Fig. S2, rows 10
to 12), split-Ub (using two orientations of test proteins vis-à-vis
NUb and CUb) was negative with hsATE1 vs. hsNTAQ1 (SI Ap-
pendix, Fig. S8).
Engineered Yeast Strains That Coexpress Human Proteins: hsATE1
R-Transferase Binds to hsUBR2 E3. Y2Hs with hsATE1 vs. full-
length hsUBR1 E3 or Nt-half of hsUBR2 (hsUBR21–1040) did
not detect their binding to hsATE1 (SI Appendix, Fig. S4, rows 1
to 6). Given these findings, and given Y2H-positive (i.e., the op-
posite) results with S. cerevisiae scATE1 vs. scUBR1 (see below), we
used co-IP to address a possible interaction between hsATE1 and
hsUBR2 that might have escaped detection by Y2H.
To carry out co-IP assays, we constructed S. cerevisiae strains
in which cDNAs encoding five components of the human Arg/
N-degron pathway were integrated into the yeast genome
downstream from constitutive or galactose-inducible promoters
(SI Appendix, Fig. S10). These strains expressed specific combi-
nations of five human proteins, tagged with different epitopes
(3fhsUBR2, 3hsvhsATE1, hsNTAN13ha, 3mychsNTAQ1, hsUBE2B),
and one strain expressed all five human proteins, as determined by
SDS/PAGE and immunoblotting with five different antibodies
(Fig. 4 A and B and SI Appendix, Table S1). Untagged hsUBE2B E2
was detected using an antibody to hsUBE2B (Fig. 4B).
In one example of this approach, we used S. cerevisiae that
expressed two (and only two) human proteins, 3fhsUBR2 E3 and
3hsvhsATE1 R-transferase (Fig. 4A, lane 3). IP of extract from
these cells was carried out using anti-hsv antibody to 3hsvhsATE1.
SDS/PAGE of anti-hsv–precipitated proteins, followed by im-
munoblotting with anti-flag antibody (specific, in this setting, for
3fhsUBR2), detected coimmunoprecipitated 3fhsUBR2 (Fig. 4C,
lanes 2 to 4). This assay was also used with an S. cerevisiae strain
that expressed all five components of the human Arg/N-degron
pathway, with the same results (Fig. 4A, lane 9, and Fig. 4C,
lanes 5 to 7).
Note that while the results of co-IP with yeast expressing solely
3fhsUBR2 and 3hsvhsATE1 (Fig. 4C, lanes 2 to 4) could be
interpreted straightforwardly as evidence for interaction between
hsUBR2 and hsATE1, a similar co-IP finding with yeast that
expressed all five human proteins (Fig. 4C, lanes 5 to 7) could
also be interpreted (in the absence of evidence with the strain
that expressed only two proteins) as a result that had been
caused by “hitchhiking” of 3fhsUBR2 within a larger complex
that contained both 3hsvhsATE1 and other coexpressed human
proteins, cited in Fig. 4 A and B.
A negative Y2H result, such as the one about hsATE1 vs.
hsUBR2 (see above), does not prove the absence of binding
(87–89). Therefore, we made a working assumption that a ro-
bustly positive result with co-IP assays (Fig. 4A, lane 3, and
Fig. 3. Y2H binding assays with enzymes of the S. cerevisiae Arg/N-degron
pathway. (A) Y2Hs in wild-type (UBR1 UFD4) S. cerevisiae. Row 1, scATE1 vs.
vector alone. Row 2, scUBR1 vs. vector alone. Row 3, scATE1 vs. scUBR1. Row
4, scNTA1 vs. vector alone. Row 5, scATE1 vs. vector alone. Row 6, scATE1 vs.
scNTA1. Row 7, scNTA1 vs. vector alone. Row 8, scATE1 vs. vector alone. Row
9, scATE1 vs. scNTA1. (B) Y2Hs in [ubr1Δ ufd4Δ] S. cerevisiae. Row 1, scUFD4
\vs. vector alone. Row 2, scUBR1 vs. vector alone. Row 3, scUFD4 vs. scUBR1. Row 4,
scUFD4 (Nt-DBD–tagged) vs. vector alone. Row 5, scUFD4 (Ct-AD–tagged) vs. vector
alone. Row 6, scUFD4 vs. scUFD4. See also the legend to Fig. 2 and SI Appendix,
Materials and Methods.
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Fig. 4C, lanes 2 to 4) was likely to signify a bona fide interaction
between hsATE1 and hsUBR2, while noting the absence of agree-
ment, in this (and only this) case, between Y2H and co-IP assays.
Another example of this co-IP approach, with the yeast strain
that expressed just two human proteins, 3fhsUBR2 E3 and its
cognate E2 enzyme hsUBE2B, was detection of interaction be-
tween these enzymes (SI Appendix, Fig. S9C).
Yet another example of co-IP approach was IP of extract from
the yeast strain that coexpressed all five human proteins (Fig. 4A,
lane 9). The result was detection, in an 3hsvhsATE1-specific anti-
hsv immunoprecipitate, of the coimmunoprecipitated hsNTA-
N13ha Asn/Nt-amidase (Fig. 4E). Considered together, co-IP data
indicated that the 3hsvhsATE1-specific anti-hsv immunoprecipitate
contained at least 3hsvhsATE1, hsNTAN13ha, 3fhsUBR2, and
hsUBE2B, a glimpse of binding patterns beyond pairwise inter-
actions (Figs. 4 A–C and E and 6A and SI Appendix, Fig. S9C). A
“complete” targeting complex remains to be characterized in vivo
and reconstituted in vitro.
hsTRIP12, a Human Sequelog of the Yeast scUFD4 E3, Does Not Bind to
hsUBR1. Previous work has shown that scUBR1, the 225-kDa
RING-type E3 N-recognin, binds to scUFD4, a 168-kDa HECT-
type E3 (Fig. 1A) (65). scUBR1 and scUFD4 function as the
double-E3 scUBR1/scRAD6–scUFD4/scUBC4/5 E3-E2 Ub li-
gase (65). One function of scUFD4 (which is not an N-recognin)
is to increase the length of a substrate-linked poly-Ub chain that
has been initiated by scUBR1 (65, 95).
The closest human sequelog of the S. cerevisiae scUFD4 E3 is
hsTRIP12 E3 (96–99). scUFD4 and hsTRIP12 are 23% identical
and 53% similar. However, Y2Hs did not detect an interaction
between hsTRIP12 and hsUBR1 (SI Appendix, Fig. S4, rows 7 to
9). Since negative Y2H results are not definitive (87–89), a po-
tential role of hsTRIP12 in the human Arg/N-degron pathway re-
mains to be addressed. With this caveat, hsTRIP12 is apparently not
a part of the human targeting complex, in contrast to S. cerevisiae, in
which scUBR1 binds to scUFD4 (65) (Fig. 3, rows 1 to 3).
The Human Cys-Dioxygenase hsADO Does Not Bind to hsUBR1,
hsUBR2, and hsATE1. In animals and plants, Nt-Cys of some Nt-
Cys–bearing proteins can be oxidized through oxygen/NO-de-
pendent reactions, yielding Nt-Cys-sulfinate or Nt-Cys-sulfonate
(Nt-Cys*). Nt-arginylation, by ATE1 R-transferase, of (oxidized)
Nt-Cys* in mammalian proteins that include G protein regula-
tors RGS4, RGS5, and RGS16, and in specific transcription
Fig. 4. Co-IPs and GST-pulldown assays with five enzymes of the human Arg/N-degron pathway. (A) Lane 1, kilodalton markers. Lanes 2 to 9, immuno-
blotting (using a mixture of relevant antibodies) of extracts from eight S. cerevisiae strains that stably coexpressed specific combinations of five human
proteins (indicated on top), including a strain that coexpressed all five proteins (lane 9). Epitope tags, indicated on the right, were used to mark these proteins
either N terminally or C terminally. The asterisk denotes a yeast protein that cross-reacted with an antibody in the mix. Untagged hsUBE2B E2 was detected by
an antibody to hsUBE2B. Of the two highly sequelogous (95% identical) E2s, hsUBE2A and hsUBE2B, only the latter was analyzed in this study. The indicated
yeast strains were constructed as described in SI Appendix, Materials and Methods and Fig. S10, through site-specific integrations, into the S. cerevisiae
genome, of human cDNAs. (B) The same as the lower part of immunoblot in A, but a higher fluorescence intensity, to increase the brightness of the hsUBE2B
bands in lanes 8 and 9. (C) Lane 1, kilodalton markers. Lane 2, detection by immunoblotting, using anti-flag, of 3fhsUBR2 in an input sample of extract from S.
cerevisiae that coexpressed 3fhsUBR2 and 3hsvhsATE1 (see lane 3 in A). Lanes 3 and 4, anti-hsv antibody-lacking (lane 3) and anti-hsv–containing beads (lane 4)
were used to immunoprecipitate proteins in the extract, followed by SDS/PAGE and immunoblotting with anti-flag antibody. Note the band of coimmu-
noprecipitated 3fhsUBR2 in lane 4 but not in lane 3. Lanes 5 to 7, same as lanes 2 to 4 but with S. cerevisiae that coexpressed all five human proteins (see also
A, lane 9). The asterisk denotes a flag-retaining proteolytic fragment of 3fhsUBR2. (D) GST-pulldown assays, with immunoblottings using anti-flag antibody.
Lane 1, kilodalton markers. Lane 2, input sample of extract from S. cerevisiae that expressed the human fhsUBR2 E3. Lanes 3 to 5, GST pulldowns with test
proteins immobilized on glutathione beads: GST alone, GST–hsNTAQ1, and hsNTAN1–GST. Note the absence of interaction between fhsUBR2 and GST. (E)
Lane 1, kilodalton markers. Lane 2, an input sample of extract from S. cerevisiae that coexpressed all five human proteins, including 3hsvhsATE1 (see also A,
lane 9, and C, lanes 5 to 7), was fractionated by SDS/PAGE and analyzed by immunoblotting with anti-ha antibody to hsNTAN13ha. Lanes 3 and 4, anti-hsv
antibody-lacking (lane 3) and anti-hsv–containing beads (lane 4) were used, respectively, to immunoprecipitate proteins in the extract, followed by SDS/PAGE
and immunoblotting with anti-ha antibody. Note the band of co-IP hsNTAN13ha in lane 4 but not in lane 3.
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factors of plants results in degradation of these proteins by the
Arg/N-degron pathway (2, 44, 73, 74, 100, 101). This pathway is
thus a sensor of oxygen and NO and regulator of responses to
these compounds (2, 100). Oxidation of Nt-Cys is mediated, at
least in part, by Nt-Cys dioxygenases (2-aminoethandiol dioxy-
genases) such as hsADO (44, 101). We used Y2H to ask whether
hsADO Nt-Cys-dioxygenase might interact with hsUBR1 or
hsUBR2 E3s, or with hsATE1 R-transferase. The results were
negative (SI Appendix, Fig. S5), suggesting (but not proving)
that hsADO dioxygenase is not a part of the human Arg/
N-degron–targeting complex.
The Human Arg-tRNA Synthetase Does Not Bind to hsUBR2 and
hsATE1. R-transferase is a part of the human Arg/N-degron–
targeting complex (Figs. 5 and 6). Since Arg-tRNA is a cosub-
strate of hsATE1 (2), and since fractionations of mammalian
cell extracts suggested the possibility of a complex between
R-transferase and Arg-tRNA synthetase (102), we used Y2Hs to
ask whether the cytosolic Arg-tRNA synthetase hsRARS might
bind to hsATE1 R-transferase or hsUBR2 E3. Negative results
of these Y2H assays (SI Appendix, Fig. S6) suggested (but did not
prove) that there is no interaction between hsRARS and either
hsATE1 or hsUBR2.
Self-Interactions Among Components of the Human Targeting
Complex. We also asked whether hsNTAQ1, hsNTAN1, and
hsATE1 (Fig. 1B) might self-interact (e.g., homodimerize). The
results were positive for Gln/Nt-amidase hsNTAQ1, but negative
for Asn/Nt-amidase hsNTAN1 and hsATE1 R-transferase (Fig. 5
and SI Appendix, Fig. S7). As described above, hsNTAQ1 and
hsNTAN1 bind to each other, and both of them also bind to
hsUBR1 (and hsUBR2) E3 (Figs. 2 and 4–7, SI Appendix, Fig. S2
and SI Appendix, S5, row 1). In the crystal structure of human
Fig. 5. Summary of binding assays and detected pairwise interactions
among five enzymes of the human Arg/N-degron pathway. Plusses and mi-
nuses indicate, respectively, a detected interaction between two indicated
human proteins, and the apparent absence of binding. nd, not determined.
Colored circles denote in vivo Y2H assays, in vivo split-Ub assays, in vitro GST-
pulldown assays, and in vitro co-IP assays, used with the indicated pairs of
proteins. In the sole case of disagreement between results of two different
assays, the binding of hsATE1 to hsUBR2 was detected by co-IP but was not
detected by Y2Hs (Fig. 4C and SI Appendix, Fig. S4, rows 1 to 6). The use, in
this study, of more than one binding assay vis-à-vis a given pair of proteins
was extensive but not exhaustive.
Fig. 6. Diagram of detected contacts (interactions) among subunits of the
human and S. cerevisiae targeting complexes in the Arg/N-degron pathway.
In A and B, each red rectangle denotes a detected interaction between a pair
of subunits. All subunits are shown as ovals whose relative sizes are roughly
proportional to subunits’ molecular masses. Specific locations of protein
contacts (red rectangles) within subunits [including E3-E3 contacts in B (65)]
are largely unknown and are placed arbitrarily. [One partially defined in-
teraction interface is between the polyacidic Ct-region of scRAD6 E2 and the
basic residue-rich region of scUBR1 E3 (109).] Since some proteins in these
complexes were found to self-interact in pairwise binding assays (see Results
and Discussion), the stoichiometries of subunits in these complexes are
known only in part. The depicted pairwise interactions in A and B are also un-
derlain by the assumption that none of these contacts are mutually exclusive. (A)
The human targeting complex: The 200-kDa hsUBR1 (or hsUBR2) E3 enzyme, the
17-kDa hsUBE2B (or hsUBE2A) E2 enzyme, the 57-kDa hsATE1 R-transferase, the
34-kDa hsNTAN1 Asn/Nt-amidase, and the 23-kDa hsNTAQ1 Gln/Nt-amidase.
Pairwise interactions identified in the present study are those of hsUBR1 (or
hsUBR2) with hsNTAN1, hsNTAQ1, hsATE1, and hsUBE2B, as well as those of
hsNTAN1 with hsNTAQ1 and hsATE1 (see Results and Discussion and Fig. 5). (B)
The S. cerevisiae targeting complex: The 50-kDa scNTA1 Asn/Gln/Nt-amidase, the
55-kDa scATE1 R-transferase, the 225-kDa scUBR1 E3, the 168-kDa scUFD4 E3, the
19-kDa scRAD6 E2, and the 16-kDa scUBC4 (or scUBC5) E2. Pairwise interactions
identified in the present study are those of scUBR1 with scNTA1, and of scNTA1
with scATE1 (see Results and Discussion). Three-dimensional crystal structures are
known for hsNTAQ1 Nt-amidase (72, 75), hsNTAN1 Nt-amidase (47), scNTA1 Nt-
amidase (62), scRAD6 E2 (110), and scUBC4 E2 (111).
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hsNTAQ1, an extended Nt-region of one hsNTAQ1 molecule in
a crystal interacts with the substrate-binding cleft of adjacent
hsNTAQ1 molecule (75), suggesting a homodimer. Given mul-
tiple pairwise interactions among specific enzymes of the present
study, a functional understanding of hsNTAQ1 self-binding (SI
Appendix, Fig. S7, rows 1, 2, and 6 to 8) would require structural
analyses of hsNTAQ1 as a part of the Arg/N-degron–targeting
complex. One possibility is that hsNTAQ1 forms a homodimer in
the absence of hsNTAN1, whereas the presence of hsNTAN1
may lead, preferentially, to the also observed hsNTAQ1–
hsNTAN1 heterodimer (Fig. 2, rows 7 to 9).
The Yeast Nt-Amidase scNTA1 Binds to scATE1 R-Transferase but Not
to scUBR1 E3.We asked whether the S. cerevisiaeArg/N-degron–targeting
complex may be larger than the previously identified scUBR1/
scRAD6–scUFD4/scUBC4/5 complex, in which two interacting E3s are
bound to their respective E2 enzymes (65, 103). scNTA1, encoding the
Asn/Gln/Nt-amidase, contains Met AUG codons at positions 1 and 11.
The sequence of scNTA1 before Met11 is similar to a typical
mitochondrial presequence, in agreement with the presence of
scNTA1 in both the cytosol/nucleus and mitochondrial matrix (61, 62,
104). Y2Hs detected the binding of scATE1 R-transferase to
scNTA1 Nt-amidase (the cytosolic version of it, initiated at Met11).
This interaction was observed with two configurations of Y2H-based
scNTA1 fusions (Fig. 3A, rows 4 to 9). Y2Hs did not detect the
binding of scNTA1 to scUBR1 E3, in all eight Nt/Ct permutations of
the DBD and AD domains linked to scNTA1 and scUBR1 (SI Ap-
pendix, Fig. S3A, rows 1 to 6).
The Yeast scATE1 R-Transferase Binds to scUBR1 E3. Y2Hs detected
the binding of scATE1 to scUBR1 (Fig. 3A, rows 1 to 3). Thus,
although the scNTA1 Nt-amidase apparently does not interact di-
rectly with scUBR1 (see above), scNTA1 would still be expected to
be a part of the targeting complex, since scNTA1 binds to
scATE1 R-transferase (Fig. 3A, rows 4 to 9), and the latter, in turn,
binds to scUBR1 (Fig. 3A, rows 1 to 3, and Fig. 6B).
The Yeast scUFD4 E3 Binds to the scUBR1 E3 N-Recognin. Previ-
ous work, mentioned above, used split-Ub and co-IP binding
assays to discover the functionally relevant double-E3 complex
Fig. 7. The possibilities of substrate channeling and superchanneling by targeting complexes of the Arg/N-degron pathway. Shown here are diagrams for
reactions mediated by the S. cerevisiae Arg/N-degron–targeting complex (Fig. 6B). The setting of the human complex (Fig. 6A) is similar. To simplify diagrams,
we left aside (as discussed in Results and Discussion) the scUFD4–scUBC4/5 part of the yeast targeting complex (scUFD4 E3 is not an N-recognin). (A) Substrate
channeling. Nt-residues are denoted by single-letter abbreviations. Yellow ovals denote the rest of a protein substrate. A chain of black ovals is a substrate-
linked poly-Ub chain. The hypothetical possibility of substrate channeling is diagrammed as a sequence of reaction/relocation steps for an (initially)
Nt-Asn-bearing substrate. The substrate is sequentially Nt-deamidated and Nt-arginylated, then relocates and binds, via its conjugated Nt-Arg residue, to
scUBR1–scRAD6 E3-E2, and is polyubiquitylated by this Ub ligase, followed by the proteasome-mediated degradation of substrate. The diagram uses notations
of transition probabilities, at each reaction/relocation step, for a molecule of an (initially) Nt-Asn-bearing substrate. P1r, P2r, and P3r denote the probabilities
of substrate moving through each reaction/relocation step while being retained (“r”) within the targeting complex (Fig. 6B). P1d, P2d, and P3d denote the
“alternative” probabilities of substrate’s dissociation (”d”), at each reaction/relocation step, into the bulk solution. An efficacious (as distinguished from weak
or nonexistent) substrate channeling would obtain, in this setting, if P1d << P1r, P2d << P2r, and P3d << P3r. (B) Superchanneling. In the hypothetical concept
of superchanneling (see Results and Discussion), the transitions (and associated probabilities) that are shown in A are “supplemented” with probabilities of
superchanneling (“sc”) transitions (P1sc, P2sc, and P3sc) at each reaction/relocation step. These transitions would result, at each step, in a bypass of downstream
steps and direct polyubiquitylation of the substrate. In the language of probability-based transitions, an efficacious superchanneling would obtain, for ex-
ample, if P1r << P1sc and P1d << P1sc; that is, if the initial binding of an Nt-Asn–bearing substrate to the complex-bound scNTA1 Nt-amidase would be rapidly
followed by substrate’s polyubiquitylation, without the necessity of (mechanistically independent) Nt modifications and accompanying physical relocations of
the substrate. Superchanneling would not occur if P1sc, P2sc, and P3sc are negligible in comparison to corresponding P1r and P1d probabilities.
Oh et al. PNAS Latest Articles | 7 of 11
BI
O
CH
EM
IS
TR
Y
D
ow
nl
oa
de
d 
at
 C
al
ifo
rn
ia
 In
st
itu
te
 o
f T
ec
hn
ol
og
y 
on
 M
ay
 5
, 2
02
0 
scUBR1–scRAD6/scUFD4–scUBC4/5 (65). We used Y2H assays
[not employed in the earlier study (65)] to confirm the binding of
scUBR1 to scUFD4 in double-mutant [ubr1Δ ufd4Δ] S. cerevisiae
that lacked the endogenous forms of these yeast E3s, thereby pre-
cluding the possibility of effects by endogenous scUBR1/scUFD4
(Fig. 3B, rows 1 to 3).
The Yeast scUBR1 E3 N-Recognin Does Not Self-Interact. Studies that
used gel-filtration assays indicated that the 225-kDa scUBR1
E3 N-recognin does not homodimerize at least in vitro (105,
106). In agreement with these results, Y2Hs with scUBR1 vs.
itself in [ubr1Δ ufd4Δ] cells also did not detect a self-interaction
of scUBR1 (SI Appendix, Fig. S3B, rows 10 to 12).
The Yeast scUFD4 E3 Self-Interacts. Y2Hs with scUFD4 vs. itself in
[ubr1Δ ufd4Δ] S. cerevisiae indicated a self-interaction (pre-
sumably homodimerization) of scUFD4 E3 (Fig. 3B, rows 4 to 6,
and SI Appendix, Fig. S3B, rows 1 to 3). At the same time, both
Y2Hs, split-Ub, and co-IP assays indicated that scUFD4 E3 also
binds to scUBR1 E3 (Fig. 3B, rows 1 to 3) (65). It is unknown
whether self-binding by scUFD4 is mutually exclusive with the
scUFD4–scUBR1 interaction. Given the apparently monomeric
state of scUBR1 in the absence of scUFD4 (105, 106) (SI Ap-
pendix, Fig. S3B, rows 10 to 12), the in vivo stoichiometry of
these (interacting) E3s in the yeast Arg/N-degron–targeting
complex remains to be determined (Fig. 6B).
The Yeast scUFD4 E3 Does Not Bind to Nt-Amidase scNTA1 and
R-Transferase scATE1. We also used Y2Hs to ask whether
scUFD4 E3 (which binds to scUBR1, forming a double-E3
complex; see above) might interact with scNTA1 Nt-amidase
and scATE1 R-transferase. Negative results (SI Appendix, Fig.
S3B, rows 4 to 9) suggested (but did not prove) that there is no
interaction between scUFD4 E3 and either scNTA1 or scATE1.
In contrast, scUBR1 interacts with scATE1 (Fig. 3A, rows 1 to
3), and is therefore expected to be indirectly bound to scNTA1 as
well, since the latter interacts with scATE1 (Fig. 3A, rows 4 to 9,
and Fig. 6B).
On Substrate Channeling in the Arg/N-Degron Pathway. A likely
function of the human and yeast Arg/N-degron–targeting com-
plexes is substrate channeling, in which a reaction intermediate
can be transferred between active sites of interacting enzymes
without release of intermediate to the bulk solution (Figs. 6 and
7A). Potential advantages of channeling include its higher kinetic
efficacy as well as protection/shielding of reactive and toxic in-
termediates (77–85). An example of direct channeling is tryp-
tophan (Trp) synthase. Its two active sites are linked by an
intraprotein tunnel. The product of the first catalyzed reaction,
indole, diffuses through the tunnel from the first to the second
active site, where Trp is formed from indole and a derivative of
serine (83).
In a different setting, called proximity channeling, and possibly
relevant to multienzyme complexes of Arg/N-degron pathways,
two or more enzymes are spatially close (e.g., through their
physical interaction), so that an intermediate produced by the
first enzyme can be captured (most of the time or some of the
time) by the second enzyme before the intermediate can diffuse
away into the bulk solution. In some settings, a proximity chan-
neling would be kinetically superior to a nonchanneled succes-
sion of the same reactions only if many quasi-identical complexes
are spatially clustered together (81).
Aggregates of complexes are indeed observed with some
multienzyme assemblies (77–85). Such aggregates include natu-
ral and dynamic associations of multiple 26S proteasome parti-
cles that occur in the bulk cytosol, inside the nucleus, and at the
nuclear envelope (ref. 107 and references therein). Interestingly,
the Arg/N-degron–targeting complexes described in the present
study (Fig. 6) apparently interact, through their E3s, with the 26S
proteasome (76) (Introduction and Concluding Remarks). If Arg/
N-degron–targeting complexes associate with naturally aggre-
gated 26S proteasomes in vivo (this remains to be determined),
such multienzyme assemblies may at least facilitate and possibly
enable the still hypothetical substrate channeling function of
targeting complexes in the Arg/N-degron pathway.
The Concept of Superchanneling. Specific features of targeting
complexes and Arg/N-degron substrates (Figs. 1, 6, and 7) led us
to a novel possibility vis-à-vis these complexes. The envisioned
mechanism, termed “superchanneling,” is mutually nonexclusive
vis-à-vis substrate channeling (Fig. 7B). We begin description of
superchanneling by noting that previously characterized cases of
substrate channeling are quite distinct from transitions that in-
volve Nt modifications of Asn, Gln, Asp, Glu, or (oxidized) Cys,
followed by downstream reactions (Fig. 1). First, an Arg/
N-degron substrate is protein-sized (i.e., it’s large and con-
formationally dynamic). Second, modification of a substrate that
immediately precedes (and causes) its capture by the 26S pro-
teasome is the formation of a poly-Ub linked to a substrate’s
cognate internal Lys residue. This reaction is not inherently se-
quential vis-à-vis the obligatorily sequential Nt modifications of,
for example, an Nt-Asn–bearing substrate (Figs. 1 and 7).
Consider the S. cerevisiae targeting complex (Fig. 6B). [The
same arguments are relevant to the human complex (Fig. 6A).]
To simplify discussion, we leave aside the scUFD4–scUBC4/5
part of the yeast complex (scUFD4 E3 is not an N-recognin)
(65). Suppose that in the (currently unknown) 3D structure of
this complex, the substrate-binding sites of scNTA1 Nt-amidase,
scATE1 R-transferase, and scUBR1–scRAD6 E3-E2 face each
other in such a way that movements of the N terminus of an
(initially) Nt-Asn–bearing substrate between these sites upon a
substrate’s successive Nt modifications involve short distances,
equal to or smaller than the sizes of protein molecules involved.
These movements would culminate in relocation of the sub-
strate’s newly acquired (conjugated) Nt-Arg residue from the
active site of scATE1 R-transferase to the complex-bound
scUBR1 N-recognin E3. We suggest that this setting may en-
able a process termed superchanneling (Fig. 7B).
Specifically, an Nt-Asn–bearing substrate would be captured,
initially, from the bulk solution by the targeting complex-bound
scNTA1 Nt-amidase (Figs. 1A and 7B). Depending on the spatial
localization and conformational mobility of a substrate’s cognate
internal lysine (i.e., the Lys residue to be polyubiquitylated), this
lysine may find itself, upon substrate’s capture by Nt-amidase, in
a stereo/catalytically favorable position vis-à-vis the active site of
the scRAD6 Ub-conjugating (E2) enzyme, which is bound to
scUBR1 E3 in the targeting complex (Fig. 7B). If so, successive
Nt modifications of the captured substrate can proceed on their
own, while the (initially) Nt-Asn–bearing substrate may be
polyubiquitylated (at the above internal lysine) either immedi-
ately or at any later time after substrate’s capture by the
complex-bound Nt-amidase. In this case, a polyubiquitylation of
the substrate would be able to bypass (i.e., would not have to wait
for) either Nt modifications of the substrate or its relocation
(after Nt-arginylation) to the Nt-Arg–binding domain of scUBR1
E3 (Figs. 1A and 7B): Hence, the term superchanneling. It refers
to the capture of, for example, an Nt-Asn–bearing substrate by
Nt-amidase, to a bypass of Nt modifications/relocations of this
substrate, to a bypass of relocation-mediated capture of Nt-
arginylated substrate by E3, and also to channeling, for exam-
ple, to the final modification (polyubiquitylation) of the substrate
without its dissociation into the bulk solution.
In this hypothetical mechanism, a major role of the targeting
complex-bound scNTA1 Nt-amidase and scATE1 R-transferase would
be their physical affinity for their cognate Arg/N-degron substrates.
This affinity may allow the complex-bound scUBR1–scRAD6 E3-E2
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to begin producing a substrate-linked poly-Ub without (necessarily)
waiting for Nt modifications and relocations of a bound substrate to
run their course.
The actual disposition, to be addressed experimentally, can
range (depending on a specific Nt-Asn–bearing protein sub-
strate) from complete absence of superchanneling to efficacious
superchanneling. In the former case, Nt modifications of a substrate
and relocation of the resulting Nt-Arg to E3 N-recognin would have
to precede the substrate’s polyubiquitylation. In the latter case,
polyubiquitylation of a substrate may become stereo/catalytically
feasible immediately after its capture by the complex-bound
Nt-amidase (Fig. 7B).
The efficacy of classic substrate channeling would be de-
termined by the rates of individual reactions within the targeting
complex vis-à-vis the rates of substrate’s escape into the bulk
solution at each reaction/relocation step. In this setting, super-
channeling may either obtain or not obtain essentially in-
dependently of whether or not a targeting complex exhibits an
efficacious substrate channeling. The envisioned, and so far hy-
pothetical, processes of substrate channeling and superchanneling
are diagrammed in Fig. 7, using notations of transition probabil-
ities for each reaction step in these mutually compatible
mechanisms.
For now, we leave aside approaches to measuring the extent of
substrate channeling in these settings and consider a way to
address the existence and efficacy of superchanneling (Fig. 7B).
Molar ratios of enzymes that reside in an Arg/N-degron–
targeting complex to their “free” counterparts in the bulk solu-
tion are unknown, awaiting measurements of this partitioning in
unperturbed in vivo settings. Outside of a targeting complex, in
the bulk solution, the enzymatic activities of scNTA1 Nt-amidase
and scATE1 R-transferase, and the Nt-Arg–binding capability of
scUBR1 E3 would be strictly required for a (later) poly-
ubiquitylation of, for example, an initially Nt-Asn–bearing sub-
strate. That is so because scUBR1 E3 would be unable to
recognize (bind to) the above substrate in the bulk solution until
after a substrate’s Nt modifications have run their course and
yielded the (conjugated) Nt-Arg residue that can be (non-
covalently) captured by scUBR1 (Figs. 1A and 7).
In contrast, the enzymatic activities of Nt-amidase and
R-transferase might be dispensable for superchanneling, which
can occur only within a targeting complex. Specifically, if
superchanneling is efficacious, the Nt-deamidation activity of the
complex-bound scNTA1 Nt-amidase would not be strictly re-
quired (or may not be required at all) for polyubiquitylation of
an (initially) Nt-Asn–bearing substrate. A nearly wild-type level
of physical affinity of scNTA1 for Nt-Asn would still be essential,
so that a substrate could be (reversibly) captured by the complex-
bound Nt-amidase and thereby (possibly) placed spatially close
to the complex-bound scUBR1–RAD6 E3-E2 Ub ligase (Figs.
1A and 7). But Nt-deamidation activity of Nt-amidase may be
dispensable in this setting, given the logic of superchanneling
model (Fig. 7B).
The crystal structure of the S. cerevisiae scNTA1 Nt-amidase
was determined by Song and colleagues (62), who also charac-
terized the active site of scNTA1. To address the hypothesis of
superchanneling, one could replace, using reverse genetics, the
scNTA1 gene with its allele that encodes a missense active-site
mutant of scNTA1 that is inactive as Nt-amidase but is essen-
tially unchanged in its affinity for Nt-Asn–bearing substrates.
Whether an enzymatically inactive scNTA1 mutant that retains
affinity for Nt-Asn is a technically realistic proposition remains
to be seen. If the Arg/N-degron pathway exhibits super-
channeling, yeast cells expressing wild-type levels of mutant
scNTA1 (enzymatically inactive but binding, in particular, to Nt-
Asn) might continue to polyubiquitylate and degrade an Nt-
Asn–bearing substrate despite the absence of Nt-deamidation
in these cells. In contrast, nta1Δ cells, which lack the entire
scNTA1 protein, would be unable to target and degrade such a
substrate, as has been shown previously (61).
Even a partial retention of polyubiquitylation and degradation
of an Nt-Asn–bearing substrate in a missense nta1 mutant that
satisfies the above constraints would suggest the existence of
superchanneling. Conversely, if an enzymatically inactive
scNTA1 protein (that retains the affinity for Nt-Asn) would be
unable to support degradation of an Nt-Asn–bearing substrate, it
would be evidence for a weak or absent superchanneling of that
substrate.
A general notion of superchanneling is as follows. Consider a
multienzyme complex that catalyzes modifications of a protein
substrate. Some of these modifications are obligatorily sequen-
tial, some are not. At least one (“last”) enzyme of the complex
can modify the substrate independently of other enzymes.
However, the last enzyme cannot bind to (i.e., does not have
affinity for) the initial substrate, whereas the first, “upstream”
enzyme of the multienzyme complex does. In such a setting, the
binding of upstream enzyme to the initial substrate may bring the
latter into a stereo/catalytically favorable proximity to the last
enzyme of the complex, thereby enabling a substrate’s modifi-
cation by the last enzyme. That modification would bypass, either
entirely or in part, the intermediate modification steps. Such a
bypass (referred to as superchanneling) may be possible within a
proximity-enabling targeting complex, but would be impossible
with free enzymes in the bulk solution. In the latter case, in-
termediate modification steps would be essential for a pro-
ductive binding of the last enzyme to the (properly modified)
substrate. We are working to verify the idea of superchanneling
and to also determine the extent of substrate channeling in the
yeast and human Arg/N-degron pathways.
Concluding Remarks. Three-dimensional structures of Arg/
N-degron–targeting complexes are unknown. This information
would be essential for a deeper understanding of these multien-
zyme assemblies. A previous study has shown that scUBR1 and
scUFD4 E3s, which bind to each other (65), also bind to the 26S
proteasome (76). That evidence, if viewed together with the pre-
sent results (Fig. 6), suggests an even larger juggernaut of an Arg/
N-degron–targeting complex that contains the proteasome as well.
Now that targeting complexes of the Arg/N-degron pathway
have been found to exist but remain to be understood, one set of
salient questions is about their dynamics and composition. How
stable (or fleeting) are these complexes in living cells? How to
detect and monitor a “complete” targeting complex in vivo?
Does assembly of these complexes require chaperones? Do these
complexes form constitutively or conditionally, depending on
cell’s metabolic state? Do they contain other components? [An
example of an untested candidate component is hsLIAT1, a
human protein of unknown function that specifically binds to
R-transferase hsATE1 (108).] It also remains to be determined
whether UBR4 (570 kDa) and UBR5 (300 kDa), two other
E3 N-recognins of the Arg/N-degron pathway in animals and
plants (Fig. 1B) (2, 24, 66–68), function as subunits of multien-
zyme complexes that are analogous to those containing UBR1
or UBR2.
Materials and Methods
For further information, see SI Appendix, SI Materials and Methods.
Yeast Strains and Genetic Techniques. S. cerevisiae strains used in this work
are described on SI Appendix, Table S1. Standard techniques were used for
strain construction and transformation.
Construction of Plasmids. The plasmids are described in SI Appendix, Table S2.
Construction details are described in SI Appendix, Materials and Methods.
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Two-Hybrid Assays. Y2H assays (87) were carried out as described previously
(9, 10, 28, 86). In both Y2H and split-Ub assays, the expression of HIS3 (a
readout of both assays), in otherwise His− cells, was a function of affinity
between test proteins.
Split-Ub Assays. Yeast-based split-Ub binding assays (93, 94) were carried out
largely as described previously (9, 28).
GST-Pulldowns. These binding assays were carried out with yeast extracts
largely as described previously (90), using, in particular, E. coli-expressed,
purified fusions of human test proteins with GST.
Co-IP Assays. These binding assays were carried out with yeast extracts largely
as described previously (90), using engineered S. cerevisiae strains that stably
coexpressed specific epitope-tagged human test proteins from their in-
tegrated cDNAs (SI Appendix, Materials and Methods).
Data Availability. All relevant data in the paper are entirely available through
both text and figures, in the main text and SI Appendix.
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